SIMON KATUMU: Open Payments
NPI 1245662048 · TACOMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,542 in 69 payments from 17 companies in 2025. Trend: 2023 $742 · 2024 $3,605 · 2025 $1,542
Food & beverage: $1,542
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $304 |
| Novo Nordisk Inc | 7 | $260 |
| Corcept Therapeutics | 14 | $216 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $158 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $76 |
| Janssen Pharmaceuticals, Inc | 3 | $67 |
| Dexcom, Inc. | 2 | $65 |
| Gilead Sciences, Inc. | 2 | $53 |
| Lilly USA, LLC | 2 | $49 |
Products named: Korlym, QULIPTA, JARDIANCE, Ozempic, LINZESS, Kerendia, XIFAXAN, SPRAVATO.
Industry payments across WA — which companies pay providers there.
